1025970-12-0

Basic information

• Product Name: (E)-3-(3-Isopropyl-1-methyl-5-methylamino-1H-pyrazol-4-ylamino)-3-[4-(2-methyl-imidazo[4,5-c]pyridin-1-yl)-phenyl]-acrylic acid ethyl ester
• Synonyms: (E)-3-(3-Isopropyl-1-methyl-5-methylamino-1H-pyrazol-4-ylamino)-3-[4-(2-methyl-imidazo[4,5-c]pyridin-1-yl)-phenyl]-acrylic acid ethyl ester
• CAS NO: 1025970-12-0
• Molecular Weight: 473.578
• Mol File: 1025970-12-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (E)-3-(3-Isopropyl-1-methyl-5-methylamino-1H-pyrazol-4-ylamino)-3-[4-(2-methyl-imidazo[4,5-c]pyridin-1-yl)-phenyl]-acrylic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-3-(3-Isopropyl-1-methyl-5-methylamino-1H-pyrazol-4-ylamino)-3-[4-(2-methyl-imidazo[4,5-c]pyridin-1-yl)-phenyl]-acrylic acid ethyl ester(1025970-12-0)
• EPA Substance Registry System: (E)-3-(3-Isopropyl-1-methyl-5-methylamino-1H-pyrazol-4-ylamino)-3-[4-(2-methyl-imidazo[4,5-c]pyridin-1-yl)-phenyl]-acrylic acid ethyl ester(1025970-12-0)

Safety Data

• Hazardous Substances Data: 1025970-12-0(Hazardous Substances Data)

Upstream product

• 29938-65-6 5-chloro-3-isopropyl-1-methyl-1H-pyrazole 
• 1026865-25-7 (5-Isopropyl-2-methyl-4-nitro-2H-pyrazol-3-yl)-methyl-amine 
• 13551-82-1 5-chloro-3-isopropyl-1-methyl-4-nitro-1H-pyrazole 
• 31272-05-6 4,5-dihydro-1-methyl-3-isopropyl-5H-pyrazol-5-one 
• 7152-15-0 ethyl 4-methyl-3-oxo-pentanoate 
• 122957-08-8 ethyl 4'-(2-methylimidazo[4,5-c]pyridin-1-yl)benzoylacetate 
• 169261-04-5 5-Isopropyl-2,N³-dimethyl-2H-pyrazole-3,4-diamine 

Relevant articles and documents

Novel Antagonists of Platelet-Activating Factor. 2. Synthesis and Structure-Activity Relationships of Potent and Long-Acting Heterofused Benzodiazepine and Diazepine Derivatives of 2-Methyl-1-phenylimidazopyridine

The optimization of in vitro activty and oral potency and duration of action in vivo is described for three novel structural types of platelet-activating factor (PAF) antagonist: benzodiazepines 5-12 onto which a variety of other heterocyclic rings were fused, pyridodiazepinones 13-26, and pyrazolodiazepinones 27-46.Compounds 5-12 were prepared by elaboration of the benzodiazepine-2-thiones 47 and 48, and 13-46 were prepared by cyclocondensation reactions of a variety of 2,3-diaminopyridine and 4,5-diaminopyrazole derivatives with ethyl 4'-(2-methylimidazopyrid-1-yl)benzoylacetate (53).The presence of imine-enamine tautomerism was observed in certain diazepine derivatives and is discussed.Structure-activity relationships were evaluated where PAF antagonist activity was measured in vitro by determining the concentration of compound (IC50) required to inhibit PAF-induced aggregation of rabbit washed platelets and in vivo by determining the oral dose (ED50) which protected mice from a lethal injection of PAF.In addition, the duration of action in conscious dogs was measured by determining the oral dose of selected compounds required to inhibit completely PAF-induced whole blood aggregation ex vivo.The most potent compound was 1,6,7,8-tetrahydro-1,8-dimethyl-5-pyrid-1-yl)phenyl>-7-oxo-3-(3-pyridyl)pyrazolodiazepine (43, UK-91,473) (IC50=2.4 nM, ED50=0.01 mg/kg po), which was found to be significantly more potent in vivo (murine lethality) than the dihydropyridine PAF antagonist 4-(2-chlorophenyl)-1,4-dihydro-3-(ethoxycarbonyl)-6-methyl-4-pyrid-1-yl)phenyl>-5-pyridine (4, UK-74,505) (ED50=0.26 mg/kg po).Compound 43 also possessed a longer duration of action than compound 4 in the conscious dog at one-fourth of the dose.The crystal structure of compound 43, established by X-ray diffraction, is reported.